BridgeMD
Tests treatment safety and results for Polypharmacy
Official title Empowering Patients to Improve Safety in Polymedication
ClinicalTrials.gov ID: NCT06956820
What this study is testing
- What it's testing
- Rationale: In current clinical practice, polypharmacy and patient empowerment are critical yet often overlooked. Polypharmacy, the chronic use of five or more drugs, poses risks such as adverse drug reactions and decreased medication adherence, especially in elderly and multimorbid patients.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- In order to be eligible to participate in this study, a subject must meet all of the following crite-ria:
- Polypharmacy defined as the use of 5 or more drugs
- Start usage of at least one index drug according to the list in table 3.
- Subject must be ≥ 18 years old
- Subject is able and willing to take part and be followed-up for at least 12 weeks
See the full eligibility criteria
- In order to be eligible to participate in this study, a subject must meet all of the following crite-ria:
- Polypharmacy defined as the use of 5 or more drugs
- Start usage of at least one index drug according to the list in table 3.
- Subject must be ≥ 18 years old
- Subject is able and willing to take part and be followed-up for at least 12 weeks
- Subject is able to donate blood or saliva
- Subject has signed informed consent A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Pregnancy or lactating
- Life expectancy estimated to be less than three months by treating clinical team
- Unable to consent to the study
- Unwilling to take part
- Subject has no fixed address
- Subject has previously been genotyped for PGx genes
- Subject has no current general practitioner
- Subject is, in the opinion of the Investigator, not suitable to participate in the study
- Estimated glomerular filtration rate (MDRD) of less than 15 ml/min per 1,73m2
- Patients with advanced liver failure (stage Child-Pugh C)
The study team makes the final eligibility decision.
Where it's taking place
- Aachen, Germany
- Heidelberg, Germany
- Pátrai, Greece
- Ljubjana, Slovenia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aachen, Germany; Heidelberg, Germany; Pátrai, Greece; Ljubjana, Slovenia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.